Inventiva Announces Preparatory Documents for Shareholders
Daix, France; New York City, NY – Inventiva (Euronext Paris and Nasdaq: IVA) is a clinical-stage biopharmaceutical company dedicated to developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH). They have recently made available key preparatory documents for their Combined General Meeting.
Details of the Combined General Meeting
Shareholders are encouraged to attend the Combined General Meeting scheduled for November 27, 2025, at 9 a.m. CEST. This important gathering will take place at Hôtel Villa M in Paris, providing an opportunity for active involvement in the company's future directions.
Agenda Highlights
During this meeting, significant topics will be discussed, including the approval of the new Chief Executive Officer’s compensation policy and considerations regarding the former CEO’s departure terms. Mr. Andrew Obenshain has been appointed to lead the company following Mr. Frédéric Cren, whose term concluded on September 30, 2025.
Preparation for the Meeting
Ahead of the meeting, the preliminary notice outlining the meeting's agenda and draft resolutions was published in the Bulletin des Annonces Légales Obligatoires and submitted for regulatory review. Shareholders can also find details on how to attend and vote at this meeting.
Access to Meeting Documents
All pertinent documents for the Combined General Meeting are accessible on Inventiva’s website under the Investors section. Furthermore, in compliance with French Commercial Code articles, critical documents will be available at the company’s registered office 15 days prior to the meeting.
Requesting Documentation
Shareholders holding registered shares can request document copies until five days prior to the meeting. Bearer shareholders must provide a shareholding certificate from their financial intermediary to exercise the same right. Additionally, shareholders may consult these documents at the company’s office by emailing a request.
About Inventiva and Its Focus
Inventiva specializes in developing innovative therapies specifically for patients suffering from MASH, a prevalent and progressive liver disease. The company is currently conducting the NATiV3 pivotal Phase 3 clinical trial, assessing lanifibranor, which is a groundbreaking pan-PPAR agonist aimed at improving outcomes for adult patients with this condition.
Investing in Future Solutions
As a publicly traded organization, Inventiva continues to drive advancements on both the Euronext Paris and the Nasdaq Global Market. The ongoing clinical trials represent an essential component of their commitment to innovation in the biopharmaceutical sector, and their vision captures the promise of providing effective treatment alternatives.
Company Contacts
Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937
ICR Healthcare
Media Relations
Alexis Feinberg
inventivapr@icrhealthcare.com
+1 203 939 2225
ICR Healthcare
Investor Relations
Patricia L. Bank
patti.bank@icrhealthcare.com
+1 415 513 1284
Frequently Asked Questions
What is the purpose of the Combined General Meeting?
The meeting aims to discuss key leadership changes and approve compensation policies and agreements concerning the CEO transition.
How can shareholders access meeting documents?
Documents are available on Inventiva’s website, and shareholders can request copies directly from the company in advance of the meeting.
What clinical trials is Inventiva currently conducting?
Inventiva is completing the NATiV3 pivotal Phase 3 trial for lanifibranor, targeting MASH treatment.
Who is the new CEO of Inventiva?
Mr. Andrew Obenshain has been appointed as the new Chief Executive Officer to lead the company.
How has the former CEO contributed to Inventiva?
Mr. Frédéric Cren significantly impacted the company’s strategy during his tenure, ensuring a smooth transition to the new leadership.
